POLBF (Poolbeg Pharma) Stock Based Compensation: $0.74 Mil (TTM As of Dec. 2025)


What is Poolbeg Pharma Stock Based Compensation?

Poolbeg Pharma POLBF Stock Based Compensation is $0.74 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Stock Based Compensation for the six months ended in Dec. 2025 was $0.26 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.74 Mil.

Poolbeg Pharma Stock Based Compensation Related Terms

Poolbeg Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Stock Based Compensation Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.32 0.52 0.06 0.79 0.73

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.00 0.34 0.45 0.48 0.26

Poolbeg Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.74 Mil.

What does a Stock Based Compensation of $0.74 Mil mean?
Poolbeg Pharma (POLBF) has a Stock Based Compensation of $0.74 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Stock Based Compensation too high?
Poolbeg Pharma's current Stock Based Compensation is $0.74 Mil.
How does Poolbeg Pharma's Stock Based Compensation compare to VRTX and REGN?
Poolbeg Pharma's Stock Based Compensation of $0.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Poolbeg Pharma and its competitors. Poolbeg Pharma's current Stock Based Compensation is $0.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Stock Based Compensation of $0.74 Mil. The current Stock Based Compensation is $0.74 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Stock Based Compensation is $0.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.